Arcturus Therapeutics vs Assembly Biosciences
Arcturus Therapeutics reported revenue of $82 million in fiscal 2025, about the same as Assembly Biosciences' $72 million in fiscal 2025. Arcturus Therapeutics' revenue fell 46.1% in its latest year, and Assembly Biosciences' grew 153.5%. Arcturus Therapeutics had an operating margin of -93.0%, against -16.8% at Assembly Biosciences. Free cash flow was −$74 million at Arcturus Therapeutics and −$41 million at Assembly Biosciences.
Side by side
| Arcturus Therapeutics | Assembly Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $82M | $72M |
| Revenue growth | −46.1% | 153.5% |
| Revenue growth a year, last 5 years | 53.9% | −1.8% |
| Gross margin | — | — |
| Operating margin | −93.0% | −16.8% |
| Net margin | −80.2% | −8.5% |
| Free cash flow | −$74M | −$41M |
| Free cash flow margin | −90.8% | −56.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.4% | 86.7% |
| Last close | $7.60 | $22.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $14,687 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arcturus TherapeuticsAssembly Biosciences
Operating margin
Percent of revenue
Arcturus TherapeuticsAssembly Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcturus TherapeuticsAssembly Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcturus Therapeutics and Assembly Biosciences pages.